Non-small cell lung cancer (NSCLC, EGFR-mutated)
- EGFR TKI is first-line for common sensitizing mutations
- Osimertinib is a major standard because CNS activity/survival
- Localized high-risk disease may use adjuvant osimertinib
- Resistance pattern guides later therapy
- Immunotherapy alone is usually less effective than in smoking-related NSCLC
- Monitor QT, cardiomyopathy + interstitial lung disease
Use at a glance
- EGFR TKI is first-line for common sensitizing mutations
Practical pearls
- Osimertinib is a major standard because CNS activity/survival
Choosing treatment
- Resistance pattern guides later therapy
- Immunotherapy alone is usually less effective than in smoking-related NSCLC
Monitoring / follow-up
- Localized high-risk disease may use adjuvant osimertinib
- Monitor QT, cardiomyopathy + interstitial lung disease
Self-check
- What is first-line treatment for Non-small cell lung cancer (NSCLC, EGFR-mutated)?
EGFR TKI.
- What should be monitored during treatment of Non-small cell lung cancer (NSCLC, EGFR-mutated)?
QT, cardiomyopathy + interstitial lung.
Drugs used for this (2)
All clinical uses · Open the interactive console ↗
